Medicare Covering Epic Sciences ctDNA Breast Cancer Panel, MDxHealth's Select MDx Test
Medicare is covering the 56-gene ctDNA panel that forms one component of the DefineMBC multiomic liquid biopsy test.
Guardant Health Gets Medicare Coverage for Liquid Biopsy Treatment Response Test
The test is designed to track circulating tumor DNA levels in blood samples, enabling clinicians to evaluate patient responses to immunotherapy.
High payment rates for tests for rare disorders in regions covered by two Medicare Administrative Contractors could spark debate about genetic testing fraud.
Guardant Health Receives Medicare Coverage for MRD Liquid Biopsy in Stage II and III Colon Cancer
The Guardant Reveal assay will now be covered for this group of patients as long as testing is initiated within three months after surgery.
Adaptive Biotech's ClonoSeq Gets Expanded Medicare Coverage For B-Cell Lymphoma
The firm's assay is the first and only test to gain coverage for this patient population, for whom ctDNA MRD assessment can help personalize treatment.